Beijing Aosaikang Pharmaceutical amends governance, eliminates supervisory committee

Beijing Aosaikang Pharmaceutical held its Second Extraordinary General Meeting of Shareholders in 2025 on September 19, 2025. Shareholders approved several key proposals, with 124 attendees representing 703,991,338 shares, or 75.8480% of total voting rights. All proposals presented were passed.

A pivotal resolution involved the revision of the company's Articles of Association, which passed with 703,804,426 votes in favor (99.9734%). This amendment eliminates the Supervisory Committee and its supervisors, with their responsibilities transferring to the Board of Directors' Audit Committee. Consequently, related internal rules like the "Rules of Procedure for the Supervisory Committee" will be abolished.

Additionally, shareholders approved a series of revisions to other governance documents, including the "Rules of Procedure for Shareholder Meetings" (99.3925% in favor), "Rules of Procedure for Board Meetings" (99.3925% in favor), "Measures for the Management of External Investments" (99.3924% in favor), "Measures for the Management of Raised Funds" (99.3917% in favor), "Related Party Transaction Management System" (99.3917% in favor), "External Guarantee Management System" (99.3906% in favor), and "Independent Directors Work System" (99.3924% in favor).